A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
Primary: -To evaluate the safety and tolerability of PBCAR19B in subjects with relapsed/refractory Non-Hodgkin Lymphoma (r/r NHL) and find an appropriate dose to optimize safety and efficacy. Secondary: -To evaluate the clinical activity of PBCAR19B in subjects with r/r NHL.
Chemotherapy (NOS); Therapy (NOS)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.